Thanks, on Jeff, everyone call and to the thanks today.
end XX% up to and of grew revenue high range. the year-over-year exceeding million, guidance quarter $XXX.X our Third
quarters, our existing our retention trailing revenue finished prior of net growth. quarter on We XX-month lead rate a basis. with to a customers to XXX% continued Similar the
retention XX our was at XXX%. net customers, top For revenue higher
our biggest, So our most sophisticated remain growing. customers fastest
we a with We least our revenue. ended XXX customers customers $XXX,XXX in contributing the a total on in increase the at revenue quarter cohort these XXX trailing a ago, from This X% XX% basis. year customers subscription-based this of XX-month and had each for accounted is
was of period. year a revenue Adjusted EBITDA new by margin represent optimization in the the XX%, outperformance, teams. year Non-GAAP profitability. million our third to XX% driven R&D third continued of non-GAAP prior to in and prior XX% Turning EBITDA our gross in engines across was infrastructure versus margin was period. the $XX.X highs adjusted $XX.X application and XX% for customer gross for and was AI quarter These strength strategic compared G&A million support and QX and EBITDA margin quarter the costs margin adjusted This our our margins. a and
$XX.X the period, in cash program. an third We to flow, repurchase to increase million year turning update of in free the million share our compared our flow cash quarter generated and prior year-over-year. on of an $XX.X sheet balance Now X%
ended a our to cash and taxes with $XXX third We cash, and of rate of cash equivalents securities. paying have are utilized As a NOLs marketable XX% roughly XX%. we at quarter the million reminder, now
as share million quarter, have $XX $XXX share Fiscal ending million repurchase repurchases we M&A. average of to of in by proceeds We shares remain worth the untouched year-to-date, XXXX. by remaining. reminder, repurchased an IPO and a price to efforts our at repurchase price our our still have free third at outstanding shares XXXX, been the December representing $XX.X During decreased over authorization from million business we recent the ending our March XX, flow. repurchased of available average fully XX, roughly have cash funded and X% million. invest have X.X These Share the quarter most And quarter an of $XX.XX. $XX.XX, diluted shares
our buying to recap season. turn I'll of a Now annual
As the their year's for represents our by largest This sales our of is significant when our annual reminder, committing marketing budgets. a next quarter pharma amount. on sign December programs, majority quarter a customers
we in we recognize primarily depending over months, XX will program these next While the on QX, signed the revenue launches. contracts timing of
brands $X brands, with last us. the strong This brand XX million-plus season, brand particularly roughly have million selling X spent this the of growth number we an brands $XX XX% cohort we increase from Of This spending each, our at with saw season, partners, of to year. we had million an million-plus one upfront least that $XX amongst these least year-over-year. $X brands increase grew at
These Care during upfront outside of sit Peer, modules We such modules also by strength Peer of than marketing in our more saw Formulary. as combined Point year-over-year XXX% to that often grew our traditional budgets, season. and
benefited on We a have our their selling from increased expand as our packaged to customers our entire newer across continue basis, modules reach focus platform. on
Now outlook. moving our on to
range of fiscal EBITDA in to million growth $XX.X million, XX% in XXXX, of revenue representing margin. $XX.X expect representing the we the million, quarter $XXX.X expect the range EBITDA fourth we of midpoint, to adjusted million at adjusted For the X% $XXX.X and a
at raising full are to the the million guidance $XXX.X growth $XXX.X our to million, XX% we of For range fiscal revenue the year, representing midpoint.
a the adjusted adjusted of range year-end. million our margin. XX% increased $XXX.X outlook to We representing EBITDA annual upsells are reflects raising $XXX.X EBITDA The million, guidance calendar at stronger-than-expected to
unlocked this past previously, than As incremental budgets mentioned typical later year.
large our our QX became Doximity As customers, for that top available, choice revenue. encouraged are those the in evident remained step-up we which is dollars in a
focused that in Looking excited modules season on fiscal are our ahead, large many the cases require will we deeper of and QX, new In getting live, selling new in which we're brands. these addition several newer investment our programs content. saw new upfront
indicative timing underlying As launch QX growth of a revenue result, more growth. program sales reflects our outlook than
pharma Based to the expect roughly market. X% we X% HCP are once outpace year again calendar grow market digital the can XXXX. in our to upfront on pharma season, our confident selling overall business We
and solutions, opportunity making investment by insights real-time encouraged level and delivering the are by are the We industry-leading continue of in innovative to customers excited ROI. our are Doximity
I will operator over the for turn it to that, With questions.